Nanobiotix Reports Promising Phase 1 Results for JNJ-1900 in Esophageal and Head Neck Cancer Therapies

Nanobiotix, a late-stage clinical biotechnology company, has reported promising Phase 1 data for its oncology product JNJ-1900 (NBTXR3), which is activated by radiotherapy and combined with other treatments. In esophageal adenocarcinoma, the combination of JNJ-1900 with photon or proton chemoradiation followed by surgery showed feasibility and safety, addressing the need for improved local control and survival while potentially reducing surgery-related complications. Updated Phase 1 results for head and neck squamous cell carcinoma (R/M-HNSCC) demonstrated encouraging efficacy and safety, with disease control and objective response rates observed in both anti-PD-1 naïve and resistant patients, suggesting potential to overcome immune checkpoint inhibitor resistance. These findings were highlighted at major oncology meetings and support further investigation in randomized controlled trials. Despite significant financial instability and declining revenues impacting Nanobiotix's stock valuation, the technical momentum and clinical data provide optimism for its therapeutic potential in multiple solid tumor indications.